Article Details
Retrieved on: 2017-12-23 23:22:30
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
<div>After $1.46 actual earnings per share reported by The Clorox Company for the previous quarter, Wall Street now forecasts -16.44% negative EPS growth. <b>Benchmark Capital</b> Advisors holds 0.32% of its portfolio in Galectin Therapeutics, Inc. for 194,200 shares. Courage Capital Management Llc owns ...</div>
Article found on:
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here